GlassScriptPhysician profile
Taimoor Hashim
NPI 1487867172
$12,304.82
in general payments reported to CMS, 2019-2025
33 companies · $468 in 2025
The $468 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $562 · 2020: $1,861 · 2021: $882 · 2022: $4,481 · 2023: $1,991 · 2024: $2,060 · 2025: $468.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,425 · Food and Beverage: $2,095.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,424.64 |
| Food and Beverage | $2,094.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $3,873.52 | 2019-2025 | Watchman Flx, Lux-Dx Insertable Cardiac Monitor |
| Abbott Laboratories | $2,414.99 | 2019-2025 | Xact, Optis, Esprit |
| Medtronic, INC. | $1,387.34 | 2023-2025 | Micra, Onyx Frontier, Venaseal |
| Medical Device Business Services, INC. | $1,169.53 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $473.70 | 2019-2023 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $454.49 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $449.22 | 2019-2023 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $411.32 | 2019-2023 | Lifevest |
| Pfizer INC. | $236.23 | 2019-2025 | |
| Amgen INC. | $215.27 | 2019-2023 | Repatha |
| United Therapeutics Corporation | $125.84 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $119.92 | 2021-2023 | Jardiance |
| Abiomed | $118.80 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $86.56 | 2019-2025 | Farxiga |
| Medtronic Vascular, INC. | $85.71 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $73.18 | 2021-2023 | |
| Actelion Pharmaceuticals US, INC. | $52.65 | 2021-2022 | |
| Akcea Therapeutics, INC. | $50.34 | 2020-2021 | |
| Alnylam Pharmaceuticals INC. | $49.38 | 2023 | Amvuttra |
| Bayer Healthcare Pharmaceuticals INC. | $47.87 | 2021-2022 | |
| Biotronik INC. | $47.26 | 2019 | |
| Edwards Lifesciences Corporation | $46.54 | 2021 | |
| Irhythm Technologies, INC. | $46.12 | 2023 | Zio Xt Patch |
| Lexicon Pharmaceuticals, INC. | $37.55 | 2023 | Inpefa |
| Philips North America LLC | $33.49 | 2019 | |
| Baxter Healthcare | $33.04 | 2023 | Coseal |
| Cvrx, INC. | $31.66 | 2022-2024 | Barostim Neo System |
| Merck Sharp & Dohme LLC | $30.57 | 2022-2023 | Verquvo |
| Shockwave Medical, INC | $25.79 | 2025 | |
| Inari Medical, INC. | $21.39 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Bridgebio Pharma, INC. | $20.57 | 2025 | Attruby |
| Kiniksa Pharmaceuticals, LTD. | $17.65 | 2023 | Arcalyst |
| Inogen, INC. | $17.33 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taimoor Hashim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.